A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma.
Hutson
Thomas E
TE
Baylor Charles A. Sammons Cancer Center/Texas Oncology, PA, Dallas, 75246, USA. thomas.hutson@usoncology.com
Bukowski
Ronald M
RM
D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary*; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D016032:Randomized Controlled Trials as Topic; D012107:Research Design
D011505:Protein-Tyrosine Kinases